Browsing by Subject "Monoamine oxidase"

Now showing items 1-9 of 9

    • 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase 
      Lühr-Sierra, Susan; Vilches-Herrera, Marcelo; Fierro, Angélica; Ramsay, Rona; Edmondson, Dale E.; Reyes Parada, Miguel; Cassels Niven, Bruce; Iturriaga-Vásquez, Patricio (ELSEVIER, 2010)
      2-Arylthiomorpholine and 2-arylthiomorpholin-5-one derivatives, designed as rigid and/or non-basic phenylethylamine analogues, were evaluated as rat and human monoamine oxidase inhibitors. Molecular docking provided ...
    • 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors 
      Lühr, Susan; Vilches Herrera, Marcelo; Fierro, Angélica; Ramsay, Rona R.; Edmondson, Dale E.; Reyes Parada, Miguel; Cassels Niven, Bruce; Iturriaga-Vásquez, Patricio (2010)
      2-Arylthiomorpholine and 2-arylthiomorpholin-5-one derivatives, designed as rigid and/or non-basic phenylethylamine analogues, were evaluated as rat and human monoamine oxidase inhibitors. Molecular docking provided insight ...
    • Amphetamine derivatives as Monoamine Oxidase Inhibitors 
      Reyes Parada, Miguel; Iturriaga Vásquez, Patricio; Cassels Niven, Bruce (Frontiers Media, 2020)
      Amphetamine and its derivatives exhibit a wide range of pharmacological activities, including psychostimulant, hallucinogenic, entactogenic, anorectic, or antidepressant effects. The mechanisms of action underlying these ...
    • Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: ... 
      Fierro, Angélica; Osorio Olivares, Mauricio; Cassels Niven, Bruce; Edmondson, Dale E.; Sepúlveda Boza, Silvia; Reyes Parada, Miguel (Elsevier Ltd., 2007-05-22)
      Abstract—Four enantiomerically pure (S)-4-alkylthioamphetamine derivatives were evaluated as monoamine oxidase (MAO) inhibitors using the human and rat isoforms of the enzyme. Molecular dockings were performed in order ...
    • Monoamine Oxidase Inhibition In the Light of New Structural Data 
      Reyes Parada, Miguel; Fierro, A.; Iturriaga-Vásquez, Patricio; Cassels Niven, Bruce (Bentham Science Publishers Ltd., 2004-11-25)
      The recent description of the crystal structures of rat MAO-A and human MAO-B provides an unprecedented framework to elucidate the mechanisms underlying the selective interactions between these proteins and their ligands. ...
    • Monoamine Oxidase Inhibitory Properties of Optical Isomers and N-substituted Derivatives of 4-methylthioamphetamine 
      Hurtado Guzmán, Claudio; Fierro, Angélica; Iturriaga-Vásquez, Patricio; Sepúlveda Boza, Silvia; Cassels Niven, Bruce; Reyes Parada, Miguel (Taylor & Francis Ltd, 2003-03-10)
      (6)-4-Methylthioamphetamine (MTA) was resolved into its enantiomers, and a series of N-alkyl derivatives of the parent compound, as well as its a-ethyl analogue, were prepared. The monoamine oxidase (MAO) inhibitory properties ...
    • Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives. ... 
      Scorza, Cecilia; Carrau, Cecilia; Silveira, Rodolfo; Zapata Torres, Gerald; Cassels Niven, Bruce; Reyes Parada, Miguel (1997)
      The monoamine oxidase (MAO) inhibitory properties of a series of amphetamine derivatives with different substituents at or around the para position of the aromatic ring were evaluated. In in vitro studies in which a crude ...
    • Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors 
      Vilches-Herrera, Marcelo; Miranda-Sepúlveda, Juan; Rebolledo-Fuentes, Marco; Fierro, Angélica; Lühr, Susan; Iturriaga-Vásquez, Patricio; Cassels Niven, Bruce; Reyes Parada, Miguel (Elsevier Ltd., 2009-02-08)
      A series of naphthylisopropylamine and N-benzyl-4-methylthioamphetamine derivatives were evaluated as monoamine oxidase inhibitors. Their potencies were compared with those of a series of amphetamine derivatives, to test ...
    • On the role of endogenous neurotoxins and neuroprotection in Parkinson's disease 
      Segura Aguilar, Juan (Medknow Publications & Media Pvt, 2017)
      For 50 years ago was introduced L-3,4-dihydroxyphenylalanine (L-dopa) in Parkinson's disease treatment and during this significant advances has been done but what trigger the degeneration of the nigrostriatal system remain ...